Endogenous Anterior Uveitis

Ophthalmology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
1 program
1
Difluprednate 0.05% ophthalmic emulsionPhase 31 trial
Active Trials
NCT01201798Completed111Est. Aug 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlconDifluprednate 0.05% ophthalmic emulsion

Clinical Trials (1)

Total enrollment: 111 patients across 1 trials

NCT01201798AlconDifluprednate 0.05% ophthalmic emulsion

Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

Start: Oct 2010Est. completion: Aug 2011111 patients
Phase 3Completed

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
3d ago

Cleanroom and Laboratory Technician

SAB BIO
3d ago

Material Handler - 8 Hour Day Shift

Pfizer
United States - Kansas - McPherson
4d ago

Senior Process Technician - Rotating 2nd Shift

Pfizer
United States - Massachusetts - Andover
4d ago
$27 - $45/hr

Staff Equipment and Systems Engineer

Johnson & Johnson
Plymouth, Minnesota, United States of America
4d ago
$94K - $152K/yr

APAC Regulatory Affairs Manager

Johnson & Johnson
Singapore, Singapore
4d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Myopia(171)Cataract(164)Glaucoma(128)Open-Angle Glaucoma(119)Dry Eye(104)Age-Related Macular Degeneration(77)Dry Eye Disease(58)Dry Eye Syndromes(50)Macular Degeneration(48)Neovascular Age-related Macular Degeneration(44)